Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 1105 for:    pharmacogenomics OR pharmacogenetics

Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03591224
Recruitment Status : Recruiting
First Posted : July 19, 2018
Last Update Posted : July 19, 2018
Sponsor:
Collaborator:
Green Shield Canada
Information provided by (Responsible Party):
John Papastergiou Pharmacy Ltd

Brief Summary:
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy. This study evaluates the effectiveness of pharmacists utilizing pharmacogenomic testing in the community pharmacy setting to help patients find the most appropriate drug therapy option(s) and minimize the risk of side effects in collaboration with prescribing physicians.

Condition or disease Intervention/treatment Phase
Depression Anxiety Major Depressive Disorder Generalized Anxiety Disorder Mood Disorders Other: Pharmacogenomic Testing Other: Pharmacist Standard of Care Not Applicable

Detailed Description:

Physicians and pharmacists have long been aware of subtle differences between patients in their responses to medications, but until recently did not have the tools to predict a patient's response to a drug before prescribing it. Many commonly prescribed medications are either ineffective or cause significant side effects for some patients. Individual variation in response to prescription drugs due to genetic factors (pharmacogenetics) is a substantial part of this serious clinical issue. Such variation in patient response ranges from failure to benefit from a drug, to adverse drug reactions, and drug-drug interactions when several drugs are taken at the same time. After years of uncertainty over the value of personalized medicine, recent studies show promising approaches for incorporating pharmacogenetics (PGx) data into routine patient care in order to reduce medication issues due to genetic factors.

Over the last decades, clinical PGx research has made significant progress in defining which genetic variations are important for influencing inter-patient variability in drug response. Evidence-based consensus therapeutic guidelines for multiple drug-gene pairs are available and promoted by the Clinical Pharmacogenetic Implementation Consortium (CPIC). Although the primary focus of PGx testing has been on improving drug selection and dosing, a secondary benefit of testing is the improvement of medication adherence.

GeneYouIn has developed the Pillcheck® drug response test that provides personalized insights on a patient's predicted response to medications. To implement the Pillcheck test, GeneYouIn is working with pharmacists who are adept in understanding pharmacogenetic terminology and can consult with prescribing physicians and patients within current scope of practice. GeneYouIn will provide educational seminars on the latest advances in pharmacogenetics and using the Pillcheck report.

This demonstration project will provide critical education to clinical pharmacists to enable utilization of patients' pharmacogenetic data for evidence-base treatment optimization. The Pillcheck report has been carefully designed to make it easy to interpret and integrate in the clinical pharmacy setting. The study will provide insights on the impact of pharmacogenetics testing on solving Drug Therapy Problems.

The Pillcheck test assesses variations in 14 genes responsible for drug transport and metabolism for over 140 commonly prescribed medications. The Pillcheck report can enable pharmacists to effectively identify Drug Therapy Problems and advise physicians on personalized treatment options thus allowing for more rational medication choices and/or dosing.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Enrolled subjects will be randomly assigned to either the control arm (pharmacist standard of care) or intervention arm (pharmacogenetic guided decision making by the pharmacist) in optimizing antidepressant drug therapy. Randomization is done by the primary investigator who isn't directly involved with patient consultations.
Masking: Double (Participant, Care Provider)
Masking Description: Patients are not told of their group assignment until the end of the study, at which point they would receive a copy of their pharmacogenetic report. The consulting pharmacist also does not have knowledge of the patient's group assignment in the first encounter for baseline data collection. Group assignment is only revealed to the pharmacist after two weeks when the pharmacogenetic report is available on the Pillcheck online portal. Patients assigned to the control group will have their report appear blank to the pharmacist, whereas the intervention patient group will have their full pharmacogenetic report accessible by the consulting pharmacist. Prescribers are also informed via fax briefly of the study protocol and asked to maintain blinding of their patient's group assignment.
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Pharmacogenomic Guided Versus Standard Pharmacist Care to Optimize Antidepressant Drug Therapy in a Community Pharmacy Setting
Actual Study Start Date : April 17, 2018
Estimated Primary Completion Date : April 17, 2019
Estimated Study Completion Date : April 17, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Arm Intervention/treatment
Active Comparator: Intervention
Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
Other: Pharmacogenomic Testing
pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
Other Names:
  • Pillcheck
  • Geneyouin

Placebo Comparator: Control
Pharmacist optimizing antidepressant therapy based on standard of care
Other: Pharmacist Standard of Care
Pharmacist providing standard of care as per usual practice




Primary Outcome Measures :
  1. Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) - general measure of satisfaction to drug therapy [ Time Frame: Change of score from baseline to 6 months ]
    This scale evaluates patient satisfaction of drug treatment for with any chronic disease. It's a brief, self-administer multidimensional generic questionnaire comprising 17 items. There are six categories of questions assessing satisfaction of (1) drug efficacy, (2) side-effects, (3) convenience of use, (4) medical care, (5) impact on activities of daily living and (6) general satisfaction. Scores of individual items range from 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A higher total score is an indication of greater satisfaction with drug therapy. Only scores from the side effects category would be summed as negative values. There is no recommended cutoff score, however is used to monitor the overall satisfaction to treatment over the period of the study.

  2. Patient Health Questionnaire (PHQ-9) - measure/monitor the severity of depression [ Time Frame: Change of score from baseline to 6 months ]
    PHQ-9 is a clinical evidence-based scale used to assess the severity of depression. There are nine diagnostic criteria for major depression based on the Diagnostic and Statistical 4th Ed. (DSM-IV) which are scored '0' (not at all), '1' (several days),'2' more than half the days, '3' (nearly every day). The nine items cover experience of pleasure, feeling down, sleep disruption, energy levels, appetite, feeling a failure, trouble concentrating, speaking slowly or being fidgety and having negative thoughts around suicide or self-harm over the previous 2 weeks. The total sum indicates depression severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe.

  3. Generalized Anxiety Disorder-7 (GAD-7) - measure/monitor the severity of anxiety [ Time Frame: Change of score from baseline to 6 months ]
    Evidence-based questionnaire used to monitor the severity of generalized anxiety. The GAD-7 score is calculated by assigning scores of '0' (not at all), '1' (several days),'2' more than half the days, '3' (nearly every day). Questions assess the tendency of feeling nervous, not being able to stop or control worrying, worrying too much about different things, trouble relaxing, being so restless that it's hard to sit still, becoming easily annoyed or irritable, feeling afraid as if something awful might happen. Total sums of 5, 10, and 15 represent mild, moderate, and severe anxiety, respectively.

  4. Sheehan Disability Scale - measure of functional impairment in work/school, social life, and family life [ Time Frame: Change of score from baseline to 6 months ]
    This scale assesses functional impairment using three 0 to 10 point visual analog scales. This can also be interpreted as percentages. Each of the three scales would have the patient represent how have their symptoms disrupted (1) work/school life, (2) social life, and (3) family life/responsibilities. The points from the 3 scales are summed as a global functional impairment score ranging from 0 (unimpaired) to 30 (highly impaired). There is no recommended cutoff score, however is used to monitor the response to treatment over the period of the study. In general, a score of 5 or greater on any of the three scales is associated with significant functional impairment.


Secondary Outcome Measures :
  1. Number of pharmacist identified drug therapy problems [ Time Frame: Analysis done at the completion of study (~1 year) ]
    Total number of Drug Therapy Problems related to antidepressant use identified by the pharmacist include the following types (1) Dose too high/overuse/abuse, (2) Dose too low, (3) Unnecessary drug therapy/duplication, (4) Adverse drug reaction / drug interaction, (5) Requires additional drug therapy, (6) Non-adherence, (7) Inappropriate drug for indication

  2. Prescriber acceptance rate of pharmacist's recommendations [ Time Frame: Analysis done at the completion of study (~1 year) ]
    Percentage of prescriber accepted pharmacist recommendations in the intervention group vs. control group



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Prescribed one or more antidepressants
  • Diagnosed with major depressive disorder and/or generalized anxiety disorder
  • Newly initiated on antidepressant therapy or a recent change in therapy and dissatisfied with therapy.
  • Experiencing adverse drug reaction(s) or suboptimal response or dissatisfaction with therapy
  • Demonstrated dissatisfaction based on a 9-item prescreening questionnaire. Scoring range from 0='not at all' to 4='very much'. If any scores for Q1-3 on side effects >2, or if any scores for Q4-6 on effectiveness <2, or if any scores for Q7-9 on overall opinion of therapy <2.

[Q1. Side effects interfere with my physical activity, Q2. Side effects interfere with my leisure activities, Q3. Side effects interfere with my daily activities, Q4. The medicine I am taking reduces my symptoms, Q5. I am satisfied with the time it takes for the medicine to start to have an effect, Q6. I feel better now than I did before starting the treatment, Q7.I intend to continue using this treatment, Q8. I feel happy with my treatment, Q9. In general, I feel satisfied with the treatment.]

Exclusion Criteria:

  • Patients with poor command of English or who are unable to provide fully informed consent
  • Liver transplant patient (cheek swab won't detect liver DNA)
  • Non-adherent to prescribed drug therapy due to reasons outside of "not feeling better" (non-medical influencing factors)
  • Diagnosis of schizophrenia, bipolar disorder, dementia
  • Patients under 18 years old

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03591224


Contacts
Layout table for location contacts
Contact: John Papaerstergiou, B.Sc.Phm 416-461-7533 ext 33 asdm994@shoppersdrugmart.ca
Contact: Wilson Li, B.Sc.Phm 416-461-7533 ext 33 wilson.li@alumni.utoronto.ca

Locations
Layout table for location information
Canada, Ontario
John Papastergiou Pharmacy Ltd - Store#500 Recruiting
Toronto, Ontario, Canada, M4C 1H6
Contact: John Papastergiou, B.Sc.Phm    416-461-2453 ext 33    asdm500@shoppersdrugmart.ca   
Contact: Wilson Li, B.Sc.Phm    416-461-7533 ext 33    psdm994@shoppersdrugmart.ca   
John Papastergiou Pharmacy Ltd - Store#994 Recruiting
Toronto, Ontario, Canada, M4J 1L2
Contact: John Papastergiou, BSc.Phm    416-461-7533 ext 33    asdm994@shoppersdrugmart.ca   
Contact: Wilson Li, B.Sc.Phm    416-461-7533 ext 33    psdm994@shoppersdrugmart.ca   
Sponsors and Collaborators
John Papastergiou Pharmacy Ltd
Green Shield Canada
Investigators
Layout table for investigator information
Principal Investigator: John Papastergiou, B.Sc.Phm University of Toronto
Study Director: Wilson Li, B.Sc.Phm John Papastergiou Pharmacy Ltd

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: John Papastergiou Pharmacy Ltd
ClinicalTrials.gov Identifier: NCT03591224     History of Changes
Other Study ID Numbers: Pro00025062
First Posted: July 19, 2018    Key Record Dates
Last Update Posted: July 19, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by John Papastergiou Pharmacy Ltd:
pharmacogenetics
pharmacogenomics
antidepressants
pharmacy
pharmacist
community
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Anxiety Disorders
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Pathologic Processes
Mental Disorders
Antidepressive Agents
Psychotropic Drugs